Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Appointed Michael Halstead as Chief Executive Officer to lead Helus Pharma through late-stage development and commercializationCompleted enrollment in the Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder (“MDD”); topline data remains on track for Q4 20261,2Announced design of u…